Patent · US Active

GlyT1 inhibitors for use in the treatment of hematological disorders

US9877963B2 · kind B2 · utility

1Cited by

0References

14Claims

0Family size

Assignee

Hoffmann-La Roche Inc. · US

Inventors

Daniela Alberati · Zofingen, CH
Annette Koerner · Weil am Rhein, DE
Emmanuel Pinard · Rixheim, FR
Michael B. WINTER · Glückstadt, DE

Key dates

Filing date	Oct 26, 2016
Grant date	Jan 30, 2018
Priority date	—
Expiry date	Oct 26, 2036

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P43/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention is related to compounds, which are GlyT1 inhibitors, for use in the treatment of hematological disorders, in particular for use in the treatment of sickle cell disease and thalassemia, or for the treatment of patients with iron overload syndromes, such as hereditary hemochromatosis.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.